company background image
RCUS

Arcus Biosciences NYSE:RCUS Stock Report

Last Price

US$25.31

Market Cap

US$1.8b

7D

14.9%

1Y

-12.8%

Updated

27 Jun, 2022

Data

Company Financials +
RCUS fundamental analysis
Snowflake Score
Valuation5/6
Future Growth5/6
Past Performance3/6
Financial Health6/6
Dividends0/6

RCUS Stock Overview

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.

Arcus Biosciences Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Arcus Biosciences
Historical stock prices
Current Share PriceUS$25.31
52 Week HighUS$49.10
52 Week LowUS$16.74
Beta1.01
1 Month Change31.89%
3 Month Change-31.60%
1 Year Change-12.84%
3 Year Change218.77%
5 Year Changen/a
Change since IPO48.88%

Recent News & Updates

May 12
Analysts Just Slashed Their Arcus Biosciences, Inc. (NYSE:RCUS) EPS Numbers

Analysts Just Slashed Their Arcus Biosciences, Inc. (NYSE:RCUS) EPS Numbers

One thing we could say about the analysts on Arcus Biosciences, Inc. ( NYSE:RCUS ) - they aren't optimistic, having...

Shareholder Returns

RCUSUS BiotechsUS Market
7D14.9%10.3%6.6%
1Y-12.8%-24.3%-18.4%

Return vs Industry: RCUS exceeded the US Biotechs industry which returned -24.3% over the past year.

Return vs Market: RCUS exceeded the US Market which returned -18.4% over the past year.

Price Volatility

Is RCUS's price volatile compared to industry and market?
RCUS volatility
RCUS Average Weekly Movement14.2%
Biotechs Industry Average Movement13.2%
Market Average Movement8.1%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.2%

Stable Share Price: RCUS is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: RCUS's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2015366Terry Rosenhttps://www.arcusbio.com

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease.

Arcus Biosciences Fundamentals Summary

How do Arcus Biosciences's earnings and revenue compare to its market cap?
RCUS fundamental statistics
Market CapUS$1.82b
Earnings (TTM)US$57.43m
Revenue (TTM)US$391.43m

31.6x

P/E Ratio

4.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
RCUS income statement (TTM)
RevenueUS$391.43m
Cost of RevenueUS$258.68m
Gross ProfitUS$132.75m
Other ExpensesUS$75.32m
EarningsUS$57.43m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.80
Gross Margin33.91%
Net Profit Margin14.67%
Debt/Equity Ratio0%

How did RCUS perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is RCUS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RCUS?

Other financial metrics that can be useful for relative valuation.

RCUS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.8x
Enterprise Value/EBITDA11.1x
PEG Ratio0.7x

Price to Earnings Ratio vs Peers

How does RCUS's PE Ratio compare to its peers?

RCUS PE Ratio vs Peers
The above table shows the PE ratio for RCUS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average603.6x
DVAX Dynavax Technologies
15.2x-25.3%US$1.6b
VSBC VitaSpring Biomedical
2377.2xn/aUS$3.1b
PRTA Prothena
19.2x1.7%US$1.3b
QURE uniQure
2.7x22.6%US$870.9m
RCUS Arcus Biosciences
31.6x47.1%US$1.8b

Price-To-Earnings vs Peers: RCUS is good value based on its Price-To-Earnings Ratio (31.6x) compared to the peer average (603.6x).


Price to Earnings Ratio vs Industry

How does RCUS's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Earnings vs Industry: RCUS is expensive based on its Price-To-Earnings Ratio (31.6x) compared to the US Biotechs industry average (15.4x)


Price to Earnings Ratio vs Fair Ratio

What is RCUS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RCUS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio31.6x
Fair PE Ratio40x

Price-To-Earnings vs Fair Ratio: RCUS is good value based on its Price-To-Earnings Ratio (31.6x) compared to the estimated Fair Price-To-Earnings Ratio (40x).


Share Price vs Fair Value

What is the Fair Price of RCUS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: RCUS ($25.31) is trading below our estimate of fair value ($325.76)

Significantly Below Fair Value: RCUS is trading below fair value by more than 20%.


Price to Earnings Growth Ratio

PEG Ratio: RCUS is good value based on its PEG Ratio (0.7x)


Discover undervalued companies

Future Growth

How is Arcus Biosciences forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

Future Growth Score

5/6

Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


47.1%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: RCUS's forecast earnings growth (47.1% per year) is above the savings rate (1.9%).

Earnings vs Market: RCUS's earnings (47.1% per year) are forecast to grow faster than the US market (13.9% per year).

High Growth Earnings: RCUS's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: RCUS's revenue (47.8% per year) is forecast to grow faster than the US market (8.4% per year).

High Growth Revenue: RCUS's revenue (47.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: RCUS is forecast to be unprofitable in 3 years.


Discover growth companies

Past Performance

How has Arcus Biosciences performed over the past 5 years?

Past Performance Score

3/6

Past Performance Score 3/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-11.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: RCUS has high quality earnings.

Growing Profit Margin: RCUS became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: RCUS has become profitable over the past 5 years, growing earnings by -11.2% per year.

Accelerating Growth: RCUS has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: RCUS has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: RCUS's Return on Equity (7.2%) is considered low.


Discover strong past performing companies

Financial Health

How is Arcus Biosciences's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: RCUS's short term assets ($1.3B) exceed its short term liabilities ($161.3M).

Long Term Liabilities: RCUS's short term assets ($1.3B) exceed its long term liabilities ($585.6M).


Debt to Equity History and Analysis

Debt Level: RCUS is debt free.

Reducing Debt: RCUS has not had any debt for past 5 years.

Debt Coverage: RCUS has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: RCUS has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is Arcus Biosciences's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate RCUS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate RCUS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RCUS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RCUS's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as RCUS has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.8yrs

Average management tenure


CEO

Terry Rosen (61 yo)

7.08yrs

Tenure

US$9,480,974

Compensation

Dr. Terry J. Rosen, Ph D., serves as Director at PACT Pharma, Inc. He co-founded Arcus Biosciences, Inc. in 2015 and has been its Chief Executive Officer since May 2015. Dr. Rosen has been the Chairman of...


CEO Compensation Analysis

Compensation vs Market: Terry's total compensation ($USD9.48M) is above average for companies of similar size in the US market ($USD5.46M).

Compensation vs Earnings: Terry's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: RCUS's management team is considered experienced (3.8 years average tenure).


Board Members

Experienced Board: RCUS's board of directors are considered experienced (3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: RCUS insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Arcus Biosciences, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Arcus Biosciences, Inc.
  • Ticker: RCUS
  • Exchange: NYSE
  • Founded: 2015
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$1.815b
  • Shares outstanding: 71.72m
  • Website: https://www.arcusbio.com

Number of Employees


Location

  • Arcus Biosciences, Inc.
  • 3928 Point Eden Way
  • Hayward
  • California
  • 94545
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/27 00:00
End of Day Share Price2022/06/27 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.